Emerging Pharmacotherapies for Diabetic Macular Edema
Joint Authors
Flynn, Harry W.
Schwartz, Stephen G.
Javey, Golnaz
Source
Experimental Diabetes Research
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-02-26
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus.
Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment.
Pharmacotherapies for DME include locally and systemically administered agents.
We review several agents that have been studied for the treatment of DME.
American Psychological Association (APA)
Javey, Golnaz& Schwartz, Stephen G.& Flynn, Harry W.. 2012. Emerging Pharmacotherapies for Diabetic Macular Edema. Experimental Diabetes Research،Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-480593
Modern Language Association (MLA)
Javey, Golnaz…[et al.]. Emerging Pharmacotherapies for Diabetic Macular Edema. Experimental Diabetes Research No. 2012 (2012), pp.1-12.
https://search.emarefa.net/detail/BIM-480593
American Medical Association (AMA)
Javey, Golnaz& Schwartz, Stephen G.& Flynn, Harry W.. Emerging Pharmacotherapies for Diabetic Macular Edema. Experimental Diabetes Research. 2012. Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-480593
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-480593
